About this item:

613 Views | 219 Downloads

Author Notes:

Reprint requests should be sent to: Paula M. Vertino, Emory University School of Medicine, 1365C Clifton Road, Rm 4086, Atlanta, GA 30322, Phone: 404-778-3119, Fax: 404-778-5530, Email: pvertin@emory.edu

The authors wish to thank Drs. Joseph Costello, Christoph Plass, Martin Brena, and Dominic Smiraglia for sharing sequence information for methylation events identified by RLGS and Dr. Paul Wade for his thoughtful critique of the manuscript.

We thank the Emory University Histology Core for technical assistance.

The authors have no conflicts of interest to report.

Subjects:

Research Funding:

This work was supported by National Cancer Institute grants CA077337 and CA116676 to PMV, funds from the National Science Foundation and NIH grant U54 RR 024380-01 to EKL, and an American Cancer Society grant PF-07-130-01-MGO and Frederick Gardner Cottrell Postdoctoral Fellowship to MTM.

PMV is a Georgia Cancer Coalition Distinguished Cancer Scholar.

Keywords:

  • DNA methylation
  • supervised learning
  • DNMT1
  • PRC2
  • polycomb
  • H3K27me3

A Multifactorial Signature of DNA Sequence and Polycomb Binding Predicts Aberrant CpG Island Methylation

Journal Title:

Cancer Research

Volume:

Volume 69, Number 1

Publisher:

, Pages 282-291

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Aberrant CpG island methylation is associated with transcriptional silencing of regulatory genes in human cancer. While most CpG islands remain unmethylated, a subset accrues aberrant methylation in cancer via unknown mechanisms. Previously, we showed that CpG islands differ in their intrinsic propensity towards hypermethylation. We developed a classifier (PatMAn) based on the frequencies of seven DNA sequence patterns that discriminated methylation-prone (MP) and methylation-resistant (MR) CpG islands. Here we report on the genome-wide application and direct testing of PatMAn in cancer. Although trained on data from a cell culture model of de novo methylation involving overexpression of DNMT1, PatMAn accurately predicted CpG islands at increased risk of hypermethylation in cancer cell lines and primary tumors. Analysis of CpG islands predicted to be MP revealed a strong association with embryonic targets of Polycomb Repressive Complex 2 (PRC2), indicating that PatMAn predicts not only aberrant methylation, but also PRC2 binding. A second classifier (SUPER-PatMAn) that integrates the seven PatMAn DNA patterns with SUZ12 protein enriched regions as a marker of PRC2 occupancy showed improved performance (prediction accuracy=81-88%). In addition to many non-PRC2 targets, SUPER-PatMAn identified a subset of PRC2 targets that were more likely to be hypermethylated in cancer. Genome-wide, CpG islands predicted to be MP were enriched in genes known to undergo hypermethylation in cancer, genes functioning in transcriptional regulation, and components of developmental pathways. These findings demonstrate that hypermethylation of certain gene loci is controlled in part by an underlying susceptibility influenced by both local sequence context and trans-acting factors.

Copyright information:

© 2009 American Association for Cancer Research.

Export to EndNote